Tickers: XTSX:VPT, PINX:VPTDF
Tags: #Technology, #Healthcare
Toronto, Ontario - TheNewswire - June 17, 2019 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company", TSXV:VPT, OTCQB:VPTDF) is proud to announce that they have completed a usability study for the VMS+ 3.0 system with very positive results.
The study was completed in Toronto with clinicians from hospitals and cardiac clinics across Ontario. Participants found the system convenient and easy to use with 100% of the clinicians reporting that it was intuitive. One user noted "Exact ejection fraction values are helpful and critical for patient management" and another commented "the 3D view is the "wow" factor".
"We are pleased with the outcome of the usability study receiving positive feedback from clinicians for our next-generation VMS+ 3.0 system. The new system design will open up cardiac imaging to new possibilities in patient comfort and clinical outcomes," noted Desmond Hirson, Ventripoint President
The VMS+ 3.0 system is a cost-effective diagnostic tool for measuring whole heart function in pediatric and adult patients utilizes standard 2D ultrasound to obtain volumetric measurements and ejection fractions for all 4 chambers of the heart. The new compact and portable system can be set up within minutes providing a streamlined approach within the clinical echo environment where patient case load is continually increasing.
Until regulatory approvals have been received, the VMS+ 3.0 system is not commercially available but is available for investigational use.
About Ventripoint Diagnostics Ltd.
Ventripoint's technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Company has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care.
For further information please contact:
Dr. George Adams, CEO, Telephone: (519) 803-6937
Forward Looking Statements:
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Corporation can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Other factors, which could materially affect such forward-looking information are described in the risk factors in the Corporation's most recent annual management's discussion and analysis that is available on the Corporation's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release
Copyright (c) 2019 TheNewswire - All rights reserved.
